Dr. Lan Mo, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 40
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 245
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 262717
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Maimonides Medical Center Brooklyn, NY
Medical groups
- Mmc Hematology Oncology Fpp (14 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 245
- Services billed
- 807
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 411 | 112 |
| Established patient office or other outpatient visit, 20-29 minutes | 44 | 35 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 40 | 21 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 25 | 25 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 23 | 22 |
| New patient office or other outpatient visit, 60-74 minutes | 20 | 20 |
| New patient office or other outpatient visit, 45-59 minutes | 17 | 16 |
| Blood smear interpretation by physician with written report | 15 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tagrisso (osimertinib mesylate) | 183 |
| Ondansetron Odt (ondansetron) Other prescribers in New York, NY | 73 |
| Eliquis (apixaban) Other prescribers in New York, NY | 61 |
| Prednisone Other prescribers in New York, NY | 60 |
| Abiraterone Acetate | 52 |
| Hydrocortisone Other prescribers in New York, NY | 39 |
| Omeprazole Other prescribers in New York, NY | 27 |
| Hydroxyurea Other prescribers in New York, NY | 26 |
| Xtandi (enzalutamide) | 24 |
| Anastrozole Other prescribers in New York, NY | 24 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 61 payments worth $5,568 in total to this clinician.
| Consulting Fee | $4,100 |
|---|---|
| Food and Beverage | $1,368 |
| Education | $99.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Sep 3, 2025 | Consulting Fee LYNPARZA · Oncology | $2,460 |
| AstraZeneca Pharmaceuticals LP Jul 7, 2025 | Consulting Fee IMFINZI · Oncology | $1,640 |
| AstraZeneca Pharmaceuticals LP May 23, 2025 | Education in-kind Company’s descriptionEducational Item | $99.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $24,021 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie Inc. · Recruiting · NCT04928846 - A Phase II, Open-label, Single-arm Study of Osimertinib as Induction therapy prior to CRT in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Stage III, Unresectable Non-small Cell Lung Cancer
AstraZeneca UK Limited - A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Eli Lilly and Company · Active, not recruiting · NCT05288166 - A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company · Recruiting · NCT06119581
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.